ARCHIMED Acquires Majority Stake in Cardioline

ARCHIMED Acquires Majority Stake in Arkstone Medical Solutions

August 6, 2025

Healthcare Services

ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Arkstone Medical Solutions, a provider of AI/ML-driven clinical decision support and antimicrobial stewardship tools. The investment will support Arkstone's product development, global expansion and R&D to accelerate adoption of its OneChoice Report in laboratories and healthcare providers worldwide.

ARCHIMED (MED Platform I) Acquires Majority Stake in CARSO

December 16, 2021

Healthcare Services

Transatlantic healthcare private equity firm ARCHIMED, via its MED Platform I fund and in partnership with CAPZA Expansion and Siparex, has acquired a majority stake in Lyon-based CARSO, a leader in purity and analytical testing for pharma, healthcare, environmental and food sectors. The deal (debt provided by Tikehau Capital and several banks) will support CARSO's internationalization and service-range expansion as the group aims to more than double current annual revenues (above €200 million).

ARCHIMED (via MED Platform I) Acquires Majority Stake in SUANFARMA

November 18, 2021

Pharmaceuticals

Transatlantic healthcare-focused private equity firm ARCHIMED, through its MED Platform I (MPI) fund, has acquired a majority stake in Madrid-based SUANFARMA, a manufacturer and distributor of active pharmaceutical ingredients (APIs) and nutraceutical ingredients. Ares Management provided debt financing for the transaction; SUANFARMA founder Héctor Ara and members of management rolled a material minority stake into the business and remain significant shareholders.

ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)

November 3, 2021

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.

ARCHIMED Acquires Majority Stake in Germany's Zyto Group

January 12, 2021

Medical Devices

ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.

ARCHIMED Acquires 75% Stake in ActiGraph

May 18, 2020

Medical Devices

ARCHIMED (ArchiMed) has acquired a 75% stake in ActiGraph in an all-equity transaction, with management retaining 10% and other historic shareholders keeping 15%. The investment will fund ActiGraph's expansion into the regulated drug-development and clinical-trials market, accelerating product, regulatory and commercial capabilities; financial terms were not disclosed.